{
    "Disease activity (follow up: 6 months; assessed with: DAS28-ESR)": {
      "No of studies": ["7"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["serious", "b"],
      "Other considerations": "none",
      "№ of patients": {
        "Switch to IL-6 (TCZ)": "58",
        "Switch to ABA": "60"
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.4 lower (0.69 lower to 0.11 lower)"
      },
      "Certainty": "  LOW",
      "Importance": "CRITICAL"
    },
    "Disability (follow up: 6 months; assessed with: HAQ-DI)": {
      "No of studies": ["7"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["very serious","c"],
      "Other considerations": "none",
      "№ of patients": {
        "Switch to IL-6 (TCZ)": "58",
        "Switch to ABA": "60"
      },
      "Effect": {
        "Relative (95% CI)": "-",
        "Absolute (95% CI)": "MD 0.12 lower (0.55 lower to 0.31 higher)"
      },
      "Certainty": " VERY LOW",
      "Importance": "IMPORTANT"
    },
    "Withdrawal due to adverse events (follow up: 6 months)": {
      "No of studies": ["7"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["very serious","c"],
      "Other considerations": "none",
      "№ of patients": {
        "Switch to IL-6 (TCZ)": "10/68 (14.7%)",
        "Switch to ABA": "4/64 (6.3%)"
      },
      "Effect": {
        "Relative (95% CI)": "RR 2.35 (0.78 to 7.13)",
        "Absolute (95% CI)": "84 more per 1,000 (from 14 fewer to 383 more)"
      },
      "Certainty": " VERY LOW",
      "Importance": "IMPORTANT"
    },
    "Serious adverse events (follow up: 6 months)": {
      "No of studies": ["7"],
      "Study design": "randomised trials",
      "Risk of bias": ["serious", "a"],
      "Inconsistency": "not serious",
      "Indirectness": "not serious",
      "Imprecision": ["very serious","c"],
      "Other considerations": "none",
      "№ of patients": {
        "Switch to IL-6 (TCZ)": "10/68 (14.7%)",
        "Switch to ABA": "4/64 (6.3%)"
      },
      "Effect": {
        "Relative (95% CI)": "RR 2.35 (0.78 to 7.13)",
        "Absolute (95% CI)": "84 more per 1,000 (from 14 fewer to 383 more)"
      },
      "Certainty": " VERY LOW",
      "Importance": "IMPORTANT"
    }
  }
  